Head-To-Head Contrast: C.R. Bard (BCR) & Transenterix (TRXC)
C.R. Bard (NYSE: BCR) and Transenterix (NASDAQ:TRXC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.
Institutional and Insider Ownership
79.3% of C.R. Bard shares are owned by institutional investors. 0.8% of C.R. Bard shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of recent recommendations and price targets for C.R. Bard and Transenterix, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
C.R. Bard currently has a consensus target price of $282.29, suggesting a potential downside of 15.45%. Transenterix has a consensus target price of $3.23, suggesting a potential upside of 13.85%. Given Transenterix’s stronger consensus rating and higher possible upside, analysts clearly believe Transenterix is more favorable than C.R. Bard.
Valuation & Earnings
This table compares C.R. Bard and Transenterix’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|C.R. Bard||$3.71 billion||6.55||$531.40 million||$7.59||43.99|
C.R. Bard has higher revenue and earnings than Transenterix. Transenterix is trading at a lower price-to-earnings ratio than C.R. Bard, indicating that it is currently the more affordable of the two stocks.
This table compares C.R. Bard and Transenterix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
C.R. Bard pays an annual dividend of $1.04 per share and has a dividend yield of 0.3%. Transenterix does not pay a dividend. C.R. Bard pays out 13.7% of its earnings in the form of a dividend. Transenterix has increased its dividend for 45 consecutive years.
Volatility and Risk
C.R. Bard has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Transenterix has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.
C.R. Bard beats Transenterix on 8 of the 14 factors compared between the two stocks.
C.R. Bard Company Profile
C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.
Transenterix Company Profile
TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.